Latest / Pricing Power Podcast with Fexingo: How Businesses Set Prices, Raise Margins, and Win Customers / How Generic Drug Pricing Collapsed a Billion-Dollar Market
Transcript
- Lucas: So a few weeks ago I was reading the earnings transcript for a mid-sized pharma company, and the CEO used the phrase 'generic erosion' eight times in one call. Eight times. And I realized, we've done episodes on Ferrari pricing, on Apple pricing, on Netflix pricing — but we've never talked about the single most brutal pricing environment in the global economy: the market for generic drugs. Luna: Brutal how? I mean, I know generics are cheaper than brand-name, but that's kind of the point, right? Lucas: It is the point. But the mechanics of how those prices get set — and how they collapse — are genuinely fascinating. And frankly, a little terrifying if you're an investor. So let's anchor on one specific drug: Daraprim. Luna: Oh, Daraprim. That's the one Martin Shkreli made famous. He hiked the price from something like 13 bucks a pill to — what, 750? Lucas: Exactly. Thirteen fifty to seven fifty. That was 2015. And the story everyone knows is the outrage — the CEO who became the 'pharma bro' villain. But what fewer people track is what happened after. Because Daraprim's pricing story is actually two stories: the hike, and then the collapse. And the collapse tells you everything about how generic drug pricing really works. Luna: Okay, so take me through the collapse. Because my assumption would be: once the price is that high, competitors would rush in and undercut. Lucas: That's exactly what should happen in a normal market. But Daraprim is a weird drug. It's used to treat a parasitic infection called toxoplasmosis, primarily in HIV patients and pregnant women. The total patient population in the US is maybe a few thousand people a year. Tiny market. So before Shkreli, the drug was essentially orphaned — only one company, Impax Labs, made it, and they barely marketed it. Luna: Right, so the low price was covering costs, but nobody was making much money. Lucas: Exactly. And Shkreli's insight — and I use that word loosely — was that with only one fda approved supplier, he had monopoly pricing power. So he bought the rights, hiked the price 5,000 percent, and dared anyone to compete. And for a while, nobody did. Because getting FDA approval for a generic is expensive — you need to prove bioequivalence, you need manufacturing capacity. For a drug with only a few thousand patients, the return on that investment is dicey. Luna: So the market failure is that the potential profit from competing is too small to justify the cost of entry, even at a 750-dollar price point. Lucas: Bingo. That's the core tension. Generic drug pricing is a prisoner's dilemma. Every potential competitor looks at the math: 'If I enter, I'll capture some market share, but the price will drop. If I stay out, the incumbent keeps the whole market but at a high price.' In theory, one competitor should enter and undercut. But in practice, the FDA hurdle and the small patient pool mean the incumbent can sustain high prices for years. Luna: So what broke the dam for Daraprim? Lucas: A company called Aurobindo, an Indian generic manufacturer, got FDA approval for a generic version in 2020. And then another company, Alvogen, followed. Suddenly you had three suppliers. And within two years, the price per pill collapsed from 750 dollars to around 10 dollars. That's a 98.7 percent drop. Luna: Wow. So the race to zero is real. But that's also good for patients, right? The drug becomes affordable again. Lucas: Absolutely good for patients. But it's a nightmare for investors who bought into the high-priced monopoly thesis. And here's the pattern: it's not just Daraprim. This happens across the entire generic drug market. The FDA has been approving generics faster — they approved a record 1,000-plus generics in 2023. And each approval adds another player, which drives prices down. The average generic drug price falls by about 80 percent after the first year of generic competition. Luna: But that's the intended outcome of the Hatch-Waxman Act, right? The 1984 law that created the modern generic drug system was designed to encourage competition after brand-name patents expire. Lucas: Exactly. And it's one of the most successful pieces of healthcare legislation in US history. Before Hatch-Waxman, generics had to go through the same full clinical trials as brand-name drugs, which was prohibitively expensive. The law created an abbreviated approval process, and it worked. Today, generics account for 90 percent of prescriptions dispensed in the US, but only about 20 percent of total drug spending. Luna: So the system works. But then why do we hear stories about generic drug shortages or price spikes on older drugs? Lucas: Because the race to zero has a dark side. When prices drop too low, manufacturers exit the market. If you're a generic drug maker and the profit margin on a drug is two percent, one quality-control issue or a raw-material cost increase can make it unprofitable. So companies stop producing. And if only one or two manufacturers remain, we get a shortage — or a price spike if one of them shuts down. That's what happened with some cancer generics during COVID. Luna: So it's a boom-bust cycle. High prices attract entrants, prices crash, suppliers leave, prices go back up. That doesn't sound very stable. Lucas: It's not. And this is where the pricing strategy gets really interesting. Some generic companies have started using what's essentially a 'value-based' approach — but in a perverse way. They target drugs with very few competitors and then price just below the incumbent, not at a deep discount. They're essentially trying to maintain a price umbrella. Luna: Right, because if you undercut by 10 percent, you capture maybe half the market at a decent margin. If you undercut by 90 percent, you capture the whole market but make almost nothing. Lucas: Exactly. So the rational strategy for a generic entrant is to price close to the incumbent, not to race to the bottom. But this only works if the other entrants also hold back. That's the prisoner's dilemma in action. If one player cheats and drops the price, everyone has to follow. And in practice, there's always a cheater. Luna: Which is why we see these cliff-edge collapses once the second or third entrant shows up. The first entrant might price high, but the second entrant knows they'll be fighting for market share, so they go aggressive. Lucas: Exactly. And this dynamic creates a really strange market structure. The first generic to enter after a brand-name drug loses patent protection gets 180 days of exclusivity — that's a huge advantage. They can price at a moderate discount to the brand, say 20 to 30 percent, and capture a ton of profit. After the exclusivity expires, more generics enter, and the price typically falls to about 20 percent of the brand price within a year. Luna: So the first generic entrant is the big winner. After that, it's a race down. Lucas: Which is why the most valuable skill in generic pharma isn't chemistry — it's regulatory strategy. You need to be the first to file an abbreviated new drug application with the FDA. The legal battles over patent challenges and exclusivity are worth billions. In 2024, the first generic for a drug called Xifaxan — used for liver disease — generated over 300 million dollars in revenue for its manufacturer in the first six months. Luna: Three hundred million from a single drug in six months. That's not a low-margin business. Lucas: No, it's not. But it's also a business where the margins can vanish overnight. And that's the fundamental pricing lesson here: in markets with low barriers to entry and high fixed costs, the first mover captures most of the value. Everyone else fights for scraps. Generic drugs are just an extreme version of that pattern. Luna: I want to zoom out for a second. Because this episode is about pricing power, and the generic drug market seems to have almost no pricing power for any individual player. So what separates the generic companies that survive and thrive from the ones that get crushed? Lucas: Great question. The survivors tend to have three things. One: a broad portfolio so they're not dependent on any single drug. Two: vertical integration into manufacturing to control costs. Three: a focus on hard to make generics — things like injectables, transdermal patches, or drugs with complex manufacturing processes. Those have fewer competitors and better margins. Luna: So basically, commoditization is a choice. If you make the same pill as everyone else, you'll compete on price. If you make something harder, you maintain pricing power. Lucas: Exactly. And that's the same lesson we've seen in almost every industry on this podcast: pricing power comes from differentiation. In generics, the differentiation is manufacturing complexity or regulatory speed. And there's one more angle I want to touch on: the role of pharmacy benefit managers, or PBMs. Luna: Ah, the middlemen. They negotiate prices with drug manufacturers for insurance plans. They're a huge part of the pricing story. Lucas: Massive. PBMs like Express Scripts, CVS Caremark, and Optum Rx control about 80 percent of prescription drug claims in the US. They have enormous leverage. They essentially say to generic manufacturers: 'We'll put your drug on our formulary — the list of covered drugs — but you have to pay us a rebate.' And because there are multiple manufacturers for most generics, the PBM can pit them against each other. Luna: So the PBMs are the ones actually enforcing the race to zero. They're the reason generic prices keep falling even when there are only two or three suppliers. Lucas: Exactly. And this has created a weird dynamic where list prices for generics actually go up in some cases, while net prices after rebates go down. Because manufacturers game the system by setting a high list price, then offering a big rebate to the PBM. The PBM gets to show employers that they're 'negotiating' discounts, and the manufacturer gets favorable formulary placement. Luna: But that only works if the manufacturer has some pricing power to begin with. If you're one of five suppliers making the same pill, the PBM doesn't need to play your game. Lucas: Right. So you see this split market: complex generics with one or two suppliers maintain decent margins, while simple generics with many suppliers get bid down to near zero. And that's where we are today — a market that's both incredibly efficient and incredibly fragile. Luna: And listeners who've been following along with this series know we've talked a lot about how pricing strategies shape entire industries. The generic drug market is a case study in how policy, regulation, and market structure combine to create a pricing environment that's almost uniquely unforgiving. Lucas: Yeah, I think that's the takeaway. If you're a business leader in any industry, the generic drug story is a warning: if your product can be replicated, and if buyers have concentration, your pricing power is temporary. Build moats — regulatory, manufacturing, or brand — or you'll end up in a race to zero. Luna: And for investors, the lesson is even sharper. Don't assume high margins are permanent. Especially in pharma. Lucas: Speaking of which, if these conversations have moved your work forward in some small way, you can support the show at buy me a coffee dot com slash fexingo. It keeps the podcast ad-free and independent. And we genuinely appreciate it. Luna: Yeah, no pressure. Just if you find value in the deep dives. Lucas: So where does this leave us? I think the next frontier in pharma pricing is value-based contracts — where the price of a drug is tied to how well it works for a specific patient. That's already happening for some expensive gene therapies. But for generics, value-based pricing is almost impossible because the price is already so low. Luna: Right, you can't tie a 10-dollar pill to outcomes in a way that makes economic sense. So the low-price equilibrium might actually be permanent for most generics. Lucas: I think it is. And that's not necessarily bad — it means the system is working as intended. But it also means that anyone investing in generic pharma needs to be very, very careful about which drugs they're betting on. The Daraprim story isn't an anomaly. It's the rule. Luna: And the rule is: pricing power is fleeting. Build your business accordingly. Lucas: Exactly. On that note, thanks for listening. We'll be back next time with another deep dive into how the world actually sets prices.